Skip to main content

Transthyretin (TTR) Amyloid Cardiomyopathy clinical trials at UCSD
1 in progress, 1 open to new patients

  • Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

    open to eligible people ages 18-90

    Phase 3 extension study to evaluate the safety of oral daily dosing of 20 mg or 80 mg tafamidis meglumine in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy

    La Jolla, California and other locations